OriCiro is focused on the development and commercialization of cell-free synthesis and amplification technology of genome-scale large DNA for applications in gene and cell-based therapies and synthetic biolog
Location: Japan, Tokyo
Total raised: $9.15M
Founded date: 2018
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.08.2021 | Series B | $9.15M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 06.06.2022 | OriCiro Announces Series B2 Financing to Advance Cell-Free D... | TOKYO, June 6, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplifica... | en.prnasia... |
| 18.05.2022 | OriCiro Genomics expand into Boston, Open new office in Nort... | TOKYO, May 18, 2022 /PRNewswire/ -- OriCiro Genomics K.K. a pioneer in cell-free synthesis and ampli... | en.prnasia... |
| 29.11.2021 | OriCiro Genomics Launches New enzymatic DNA synthesis tool f... | TOKYO, Nov. 29, 2021 /PRNewswire/ -- OriCiro Genomics Inc., a pioneer in cell-free synthesis and amp... | en.prnasia... |
| 23.07.2021 | OriCiro Genomics Raises ¥800M in Series B Financing | OriCiro Genomics, a Tokyo, Japan-based pioneer in cell-free synthesis and amplification of genome-sc... | finsmes.co... |
| 20.07.2021 | OriCiro Announces ¥1 Billion Series B Financing to Advance C... | TOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplif... | prnewswire... |
| 20.07.2021 | OriCiro Announces ¥1 Billion Series B Financing to Advance C... | TOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplific... | marketscre... |
| 20.07.2021 | OriCiro Announces ¥1 Billion Series B Financing to Advance C... | TOKYO, July 20, 2021 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplific... | en.prnasia... |
| 30.09.2020 | OriCiro Launches World's First Cell-Free Amplification Techn... | TOKYO, Sept. 30, 2020 /PRNewswire/ -- OriCiro Genomics, a pioneer in the cell-free synthesis and a... | prnewswire... |